Funda Yılmaz

Funda Yılmaz

Auto-generated profile, based on publicly available information

Funda Yılmaz

UNIVERSITY OF HEALTH SCIENCES, ERZURUM REGION HEALTH RESEARCH CENTER

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 December 2023 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
PDF file
GIGülşen İsKender
Gülşen İsKender
DMDuygu Mert
Duygu Mert
GTGöknur Yapar Toros
Göknur Yapar Toros
FYFunda Yilmaz
Funda Yilmaz
EBErsin Bozan
Ersin Bozan
MEMustafa Ertek
Mustafa Ertek
Background/aim:It wasaimed herein to investigate coronavirus disease (COVID-19) in cancer patients and compare hematological and solid organ cancer patients in terms of the course and outcome of this disease. Materials and methods:Data from cancer patients with laboratory-confirmed COVID-19 infection were analyzed retrospectively. Risk factors for poor prognosis and the effect of vaccination on the clinical outcomes of the patients were evaluated. Results:A total of 403 cancer patients who were diagnosed with COVID-19 between March 1st, 2021, and November 30th, 2022, were included, of whom 329 (81.6%) had solid and 74 (18.4%) had hematological cancers. Hospitalization and intensive care unit (ICU) admission rates were significantly higher in the hematological cancer patients compared to the solid organ cancer patients (73.0% vs. 35.9%, p< 0.001 and 25.7% vs. 14.0%, p= 0.013, respectively). The COVID-19-related case fatality rate (CFR) was defined as 15.4%, and it was higher in the hematologicalcancer patientsthan inthe solid organ cancer patients (23.0% vs. 13.7%, p= 0.045) and was higher in patients with metastatic/advanced disease compared to the other cancer stages (p< 0.001). In the solid organ cancergroup, hospitalization, ICU admission, and the COVID-19 CFR were higher in patients with respiratory and genitourinary cancers (p< 0.001). A total of 288 (71.8%) patients had receivedCOVID-19 vaccination; 164 (56.94%) had≤2 doses and 124 (43.06%) had≥3 doses.The hospitalization rate was higher in patients with ≤2 doses of vaccine compared to those with ≥3 doses (48.2% vs. 29.8%,p= 0.002). Patients with COVID-19- related death had higher levels of leucocyte, neutrophil, D-dimer, troponin, C-reactive protein (CRP), procalcitonin, and ferritin and lower levels of lymphocyte than the survivors. In the logistic regression analysis,the risk of COVID-19-related mortality was higher in the hematological cancer patients(OR:1.726), those who were male (OR:1.757), and with the Pre-Delta/Delta variants (OR:1.817). Conclusion:This study revealed that there is an increased risk of COVID-19-related serious events (hospitalization, ICU admission, or death) in patients with hematological cancerscompared with those who have solid organ cancers. It wasalso show cine is more protective against severe illness and the need for hospitalization than ≤2 doses.

30 June 2025 in TURKISH JOURNAL of CLINICS and LABORATORY
Verified
Journal Article
Open access
PDF file
SKSeda Kahraman
Seda Kahraman
MHMutlu Hızal
Mutlu Hızal
ÖGÖzge Gümüşay
Özge Gümüşay
GBGül Başaran
Gül Başaran
MSMustafa Seyyar
Mustafa Seyyar
MSMehmet Ali Nahit SENDUR
Mehmet Ali Nahit SENDUR
Aim: Hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative breast cancer which represents the most common subgroup of metastatic breast cancer (MBC). Recently, further subclassification for HER2-negative tumors has emerged as HER2-low. There is limited knowledge regarding the effect of HER2-low expression on outcomes of patients with HR-positive and HER2-negative MBC treated with CDK 4/6 inhibitors plus hormonal therapy. Therefore, we evaluated survival parameters according to HER2-low status for this patient group in this study. Material and Methods: As the Turkish Oncology Group (TOG) Project, retrospectively collected data from 423 patients with HR-positive/HER2-negative MBC treated with ribociclib and palbociclib plus letrozole therapy was assessed. Included patients had metastatic first-line therapy and endocrine-sensitive disease. Survival outcomes were compared between HER2-negative and HER2-low patient groups. Conclusion: HER2-low status had no statistically significant impact on survival in patients treated with palbociclib or ribociclib plus letrozole.

1 March 2021 in European Archives of Medical Research
Verified
Journal Article
Closed access
FYFunda Yılmaz
Funda Yılmaz
BOBerna Oksuzoglu
Berna Oksuzoglu

6 January 2026 in Anatolian Current Medical Journal
Verified
Journal Article
Open access
ADAyşegül Dumludağ
Ayşegül Dumludağ
İBİrfan Buğday
İrfan Buğday
FYFunda Yılmaz
Funda Yılmaz
Aims: Chemotherapy-related hypersensitivity reactions (HSRs) range from mild symptoms to life-threatening anaphylaxis. Accurate differentiation is essential for treatment decisions. This study aimed to evaluate the diagnostic value of combining serum tryptase levels with a standardized clinical severity score in patients who developed chemotherapy-induced HSRs. Methods: This retrospective, single-center study included adult cancer patients who developed HSRs during chemotherapy and underwent serum tryptase testing within 1-4 hours of symptom onset. Anaphylaxis severity was classified using Brown’s scoring system. The relationship between tryptase levels, clinical severity, and subsequent treatment modifications was analyzed, and diagnostic performance for predicting severe anaphylaxis was assessed using ROC analysis. Results: Ninety-seven patients were included. Elevated tryptase levels (≥11.4 ng/ml) were detected in 38% of patients and were strongly associated with severe anaphylaxis scores (≥5) (p